Back to News
Market Impact: 0.2
Sandoz Partners With MAbxience On Emicizumab Biosimilar; Pipeline Reaches 40 Assets
Source: Nasdaq
Healthcare & BiotechProduct LaunchesTechnology & Innovation
Sandoz Group announced a collaboration with mAbxience to develop a proposed emicizumab biosimilar. The partnership expands Sandoz's affordable-medicines pipeline and could support its position in biosimilars, though no financial terms, development timeline, or regulatory details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
SDZ0.45
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is over
- Apple's quarter is not perfect. But with enough to like, we raised our price target
- California’s Bay Area debates data centres ahead of US midterm elections